Join Growin Stock Community!

冠亞6758.TW Overview

TW StockBiotech. & Medical
(No presentation for 6758)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

冠亞（6758）Overall Performance

冠亞（6758）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

冠亞（6758） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

冠亞（6758）Key Information

冠亞（6758）Profile

A-SPINE Asia Co., Ltd., a medical device company, engages in the research, development, manufacture, and marketing of spinal implants and instruments in Taiwan, China, the Philippines, Australia, New Zealand, Iran, Vietnam, Indonesia, Spain, Trinidad, and Sri Lanka. The company offers spinal fixation systems, such as cervical anterior fixation, and thoracic and lumbar fixation systems; interbody fixation systems, including ACDF cages, PLIF and TLIF cages, and ALIF lumbar cages; balloon kyphoplasty products; and vertebral body replacement products. It also sells imported orthopedic medical devices. The company was founded in 2001 and is based in New Taipei City, Taiwan.

冠亞（6758）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.43
PE Ratio (TTM)
27.41
Forward PE
-
PS Ratio (TTM)
0.64
PB Ratio
1.96
Price-to-FCF
5.63
METRIC
VALUE
vs. INDUSTRY
Gross Margin
74.53%
Net Margin
2.33%
Revenue Growth (YoY)
29.05%
Profit Growth (YoY)
29.41%
3-Year Revenue Growth
5.88%
3-Year Profit Growth
2.22%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.43
PE Ratio (TTM)
27.41
Forward PE
-
PS Ratio (TTM)
0.64
PB Ratio
1.96
Price-to-FCF
5.63
Gross Margin
74.53%
Net Margin
2.33%
Revenue Growth (YoY)
29.05%
Profit Growth (YoY)
29.41%
3-Year Revenue Growth
5.88%
3-Year Profit Growth
2.22%
default symbol

6758

冠亞

39.10D

-3.58%

(-0.04)

  • When is 6758's latest earnings report released?

    The most recent financial report for 冠亞 (6758) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6758's short-term business performance and financial health. For the latest updates on 6758's earnings releases, visit this page regularly.

  • Where does 6758 fall in the P/E River chart?

    According to historical valuation range analysis, 冠亞 (6758)'s current price-to-earnings (P/E) ratio is 41, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much cash does 6758 have?

    At the end of the period, 冠亞 (6758) held Total Cash and Cash Equivalents of 67.22M, accounting for 0.13 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6758 go with three margins increasing?

    In the latest report, 冠亞 (6758) achieved the “three margins increasing” benchmark, with a gross margin of 73.15%%, operating margin of 5.36%%, and net margin of 3.94%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6758's profit trajectory and future growth potential.